用于ADC药代动力学生物分析的通用LC-MS/MS方案

Originally published by Crystal Bio Solutions. Republished with company attribution. Original technical perspectives, references and source links are retained.

Antibody-Drug Conjugates (ADCs) combine the targeting power of monoclonal antibodies with the potency of small-molecule drugs, making them one of the most promising modalities in oncology. However, their complex structures and pharmacological properties present unique challenges in production, characterization, and PK analysis.

At Crystal Bio Solutions, our experts designed and validated a generic LC-MS/MS solution that enables accurate, timely, and reproducible measurement of total antibody, conjugated payload, and free payload. This method provides the sensitivity and specificity required to support ADC development from early non-clinical research through clinical trials.

The Challenge of ADC PK Bioanalysis

Developing robust PK assays for ADCs requires overcoming several obstacles:

• Tight development timelines for supporting rapid program advancement
• Complex LC-MS sample preparation steps that increase variability
• The need to validate assay parameters including accuracy, precision, sensitivity, specificity, and stability across multiple analytes (antibody, conjugated payload, free payload)

These challenges highlight the importance of a generic, adaptable solution that can streamline ADC bioanalysis.

Establishing a Generic LC-MS/MS Workflow: A Case Study

Our experts created a workflow capable of simultaneously quantifying total antibodies, conjugated payload, and free payload with high sensitivity and reproducibility. By optimizing sample preparation and LC-MS conditions, we established a method that is both generic (applicable to a wide range of ADCs) and tailored enough to deliver regulatory-ready data.

Sensitive, Accurate, and Validated ADC PK Assay

The fully validated LC-MS/MS solution demonstrated:

• High sensitivity and specificity, ensuring reliable detection across analytes
• Accuracy and precision meeting regulatory expectations
• Robust stability for consistent results in both non-clinical and clinical studies
• A workflow adaptable to multiple ADC formats within accelerated timelines

Why PK Analysis Matters for ADC Drug Development

ADCs are among the most complex therapeutic modalities under development today. Without validated PK assays, developers risk delays in understanding exposure, efficacy, and safety. By providing a generic and adaptable LC-MS/MS solution, our team helps streamline ADC bioanalysis, supporting faster decision-making, de-risking clinical programs, and ultimately accelerating delivery of novel therapies to patients.

Key Takeaways

• Developed a generic LC-MS/MS workflow for ADC PK bioanalysis
• Simultaneous quantification of total antibody, conjugated payload, and free payload
• Validated with high sensitivity, accuracy, precision, and stability
• Provides a robust, adaptable solution to support both non-clinical and clinical ADC studies

📥📎 Access the case study

Read the original article and source figures